FDA approves Abecma for relapsed, refractory multiple myeloma
by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Updated on: April 28,2024
0

FDA approves Abecma for relapsed, refractory multiple myeloma
by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Updated on:April 28,2024
0
